b By CLSI interpretive criteria, anidulafungin and micafungin MICs determined by various methods were sensitive (60 to 70%) and highly specific (94 to 100%) for identifying FKS mutations among 120 Candida glabrata isolates. Anidulafungin and micafungin breakpoints were more specific than CLSI's caspofungin breakpoint in identifying FKS mutant strains and patients with invasive candidiasis who were likely to fail echinocandin treatment (P < 0.0001 for both). Echinocandin MICs were most useful clinically when interpreted in the context of prior echinocandin exposure.
T
he echinocandins are the front-line therapy for invasive candidiasis due to Candida glabrata (1) , but resistance to the class is emerging (2, 3) . Resistance is mediated by point mutations in hot spots of FKS genes, which encode the echinocandin target enzyme ␤-1,3-D-glucan synthase. Recently, the Clinical and Laboratory Standards Institute (CLSI) proposed revised echinocandin MIC breakpoints to differentiate FKS mutant from wild-type Candida strains (4, 5) . Using MICs determined by the standard broth microdilution method with RPMI medium (BMD-RPMI), we recently showed that the revised caspofungin resistance breakpoint (Ͼ0.12 g/ml) was highly sensitive but poorly specific for identifying FKS mutant C. glabrata strains at our center (2, 6) . In fact, the distributions of caspofungin MICs by the standard method have differed between laboratories (4, 6-11) and may be impacted by factors such as choice of dissolving solvent (12) and evaluator interpretation (7) . In response to our suboptimal results, we determined receiver operator characteristic (ROC)-derived caspofungin resistance breakpoints for identifying FKS mutant C. glabrata by several testing methods. A caspofungin MIC of Ͼ0.25 g/ml by Etest performed best, with sensitivity and specificity of 100% and 94%, respectively (2) . In the setting of previous echinocandin exposure, 91% of patients who had invasive candidiasis due to caspofungin-resistant C. glabrata failed caspofungin treatment. Therefore, caspofungin MICs against C. glabrata were clinically useful at our center, but the CLSI resistance breakpoint was not.
Due to interlaboratory variability in the MIC ranges for caspofungin, susceptibility testing of other echinocandins (anidulafungin and micafungin) has been advocated as a surrogate for identifying caspofungin-resistant C. glabrata strains (13, 14) . To investigate the utility of anidulafungin and micafungin MICs, we tested C. glabrata strains from patients with invasive candidiasis by the methods used in our earlier study (2) and assessed the performances of revised CLSI and ROC-derived breakpoints. We determined if anidulafungin or micafungin MICs correlated with the presence of C. glabrata FKS mutations and treatment outcomes among patients and compared the results with our previous caspofungin MIC data.
Hot spot regions of FKS1 and FKS2 were sequenced in 120 C. glabrata isolates selected from the biorepository at the University of Pittsburgh Mycology Research Unit, as described previously (2) . Anidulafungin and micafungin powders obtained from Pfizer (New York, NY) and Astellas (Northbrook, IL), respectively, were dissolved in dimethyl sulfoxide (DMSO). MICs were determined in triplicate by standard methods according to CLSI document M27-A3 (BMD-RPMI medium, buffered to a pH of 7.0 with MOPS [morpholinepropanesulfonic acid]) (15) . MICs against quality control strains Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019 were within the expected range during each experiment (16) . Eight percent (10/120) of isolates harbored FKS1 mutations (n ϭ 3 [D632H, D632Y, and R635I]) or FKS2 mutations (n ϭ 7 [3 F659L isolates, 2 F659del isolates, and F659S and S663P]). As we previously reported, 100% of mutant C. glabrata isolates were recovered from patients previously exposed to an echinocandin (compared to 19% [21/110] of wild-type isolates; P Ͻ 0.0001); the rate of FKS mutations among isolates from patients who were previously exposed to an echinocandin was 32% (10/31) (2) . Median anidulafungin and micafungin MICs were higher against isolates from patients with previous echinocandin exposure (P ϭ 0.0005 and 0.003, respectively) ( Fig. 1 ) and against FKS mutant strains (P Ͻ 0.0001 for both) ( Table 1) .
MICs measured using the standard BMD-RPMI method were compared to those determined by BMD in antibiotic medium 3 (BMD-AM3), Etest (bioMérieux, Durham, NC), and Sensititre YeastOne (Trek Diagnostics, Cleveland, OH). For each method, essential agreement with BMD-RPMI was defined by MICs within 1 dilution (Յ2-fold difference). Anidulafungin MICs ranged from 0.015 to 4 g/ml by the various methods (Table 1) . Based on the CLSI interpretive breakpoint (Ͼ0.12 g/ml), the highest and lowest rates of resistance were 9% (11/120) and 1% (1/120) by YeastOne and BMD-AM3, respectively. Essential agreement was highest with Etest (94%) and lowest with BMD-AM3 (78%; P ϭ 0.0001 by McNemar's test). Each of the four methods was highly specific for the identification of FKS mutants (range, 96 to 100%) ( Table 2 ). Sensitivity ranged from 60 to 70% for BMD-RPMI, YeastOne, and Etest but was 10% for BMD-AM3 (P ϭ 0.04). ROC-derived breakpoints improved sensitivity to 60 to 90% at little or no cost to specificity. An anidulafungin resistance breakpoint of Ͼ0.06 g/ml by Etest performed best (90% sensitive and 98% specific).
Micafungin MICs also ranged from 0.015 to 4 g/ml by the various methods. The highest and lowest rates of resistance, as determined using the CLSI resistance breakpoint (Ͼ0.06 g/ml), were 11% (13/120) and 2% (2/120) with BMD-RPMI and BMD-AM3, respectively (Table 1 ). There were no differences in rates of essential agreement (range, 85 to 88%). The sensitivity of the CLSI breakpoint for identifying FKS mutants was 60% for BMD-RPMI, YeastOne, and Etest, with specificity ranging between 94 and 100% ( Table 2) . Sensitivity was 20% for BMD-AM3, with specificity of 100%. ROC-derived micafungin breakpoints demonstrated sensitivity of 70 to 80% and specificity of 91 to 98%. A micafungin resistance breakpoint of Ͼ0.03 g/ml by YeastOne performed best (80% sensitive and 95% specific).
Next, we evaluated the performance of MICs against strains recovered from 66 patients with invasive candidiasis who were treated with an echinocandin (caspofungin, n ϭ 63; anidulafungin, n ϭ 1; micafungin, n ϭ 2), including all patients infected with FKS mutant C. glabrata strains. Patient outcomes were assessed as described previously (2, 6) and defined using consensus definitions (17) . Eighty-six percent (57/66) and 14% (8/66) of patients had candidemia and deep-seated candidiasis, respectively. The median age was 42 years (range, 25 to 77 years); 30% (20/66) of patients were men, 42% (28/66) resided in the intensive care unit (ICU) at the time of candidiasis, and 23% (15/66) were solid organ transplant recipients. The 14-day treatment success and failure rates were 67% (44/66) and 33% (22/66), respectively. The sensitivity and specificity of anidulafungin and micafungin breakpoints for identifying treatment failures by each method are listed in Table 3 . Based on CLSI breakpoints, the sensitivity and specificity of anidulafungin MICs by BMD-RPMI, YeastOne, and Etest ranged from 23 to 27% and 93 to 98%, respectively. Anidulafungin MICs by BMD-AM3 had sensitivity of only 5% and specificity of 100%. The sensitivities of micafungin MICs by BMD-RPMI, YeastOne, and Etest also ranged from 23 to 27%; specificity ranged from 88 to 98%. BMD-AM3 sensitivity and specificity were 9% and 100%, respectively. ROC-derived anidulafungin and micafungin resistance breakpoints had improved sensitivities of 23 to 36% and 27 to 36%, respectively. The highest sensitivity was 36% (8/22) for an anidulafungin MIC of Ͼ0.06 g/ml by Etest and a micafungin MIC of Ͼ0.03 g/ml by YeastOne. The specificity of results by these methods was 95% (42/44). Of note, the sensitivities of an FKS mutation or prior echinocandin exposure in identifying treatment failures were 41% (9/22) and 59% (13/ 22), respectively (P ϭ 1.00 and 0.07, respectively, versus anidulafungin Etest or micafungin YeastOne). The corresponding specificities were 98% (43/44) and 82% (36/44).
Eighty percent (8/10) of patients infected with an isolate for which the anidulafungin Etest MIC was Ͼ0.06 g/ml failed echinocandin treatment, compared to 25% (14/56) of patients infected by an isolate with a MIC of Յ0.06 g/ml (P ϭ 0.002). Likewise, 78% (7/9) of patients infected with an isolate for which the micafungin YeastOne MIC was Ͼ0.03 g/ml failed treatment, compared to 26% (15/57; P ϭ 0.005) of patients infected by an isolate with a MIC Յ0.03 g/ml. The echinocandin failure rate among patients infected with an FKS mutant C. glabrata strain was 90% (9/10), compared to 23% (13/56) for patients infected with wild-type C. glabrata (P ϭ 0.0003). The failure rate for patients who were previously exposed to an echinocandin was 62% (13/ 21), compared to 30% (9/44) for patients without prior exposure (P ϭ 0.001). Flowcharts for treatment outcomes stratified by prior echinocandin exposure and echinocandin MICs (as measured using the most sensitive testing method for each agent) are presented in Fig. 2 .
Taken together, our data demonstrate that anidulafungin and micafungin MICs determined by the standard BMD-RPMI method at our center were similar to those used by CLSI to establish revised interpretive breakpoints (4). As such, the recommended MIC breakpoints were sensitive and highly specific for identifying FKS mutant strains as resistant. These data stand in contrast to the poor performance we reported previously for the CLSI caspofungin resistance breakpoint (sensitivity and specificity of 90% and 3%, respectively) (2). Moreover, CLSI anidulafungin and micafungin breakpoints were more specific (98% [43/44] and 89% [39/44], respectively) than the caspofungin breakpoint (0% [0/44]) in identifying echinocandin treatment failures (P Յ 0.0001 for both). Our findings have two important implications. First, clinicians should understand the distribution of echinocandin MICs at their centers and evaluate the performance of CLSI breakpoints accordingly. Second, CLSI anidulafungin or mica- fungin breakpoint MICs may be useful markers for echinocandin resistance at centers where caspofungin MICs run higher than the range used by CLSI. The present study is in keeping with the European Committee on Antimicrobial Susceptibility's (EUCAST) recommendation that caspofungin MICs not be used to identify echinocandin resistance (13, 14) .
It is notable that ROC-derived breakpoints for anidulafungin and micafungin slightly improved the identification of FKS mutant strains and echinocandin treatment failures. The sensitivity and specificity of these breakpoints, as determined using the standard testing method, were comparable to our previous data for ROC-derived caspofungin breakpoints (70% sensitive and 93% specific for FKS mutants and 32% and 86%, respectively, for treatment failures) (2) . The ROC-derived anidulafungin and micafungin breakpoints were 1 dilution lower than CLSI breakpoints and in agreement with EUCAST breakpoints. In contrast, the ROCderived caspofungin breakpoint was 2 dilutions higher than the CLSI breakpoint, which further highlights the extent to which differences in MIC distributions between centers can impact the interpretation of data (11) .
Commercial susceptibility testing methods for anidulafungin and micafungin also performed well. Etest and YeastOne provided a high degree of essential agreement and comparable sensitivity and specificity to BMD-RPMI for identifying FKS mutations. The data are consistent with prior studies and support conclusions that the three tests can be used interchangeably for anidulafungin and micafungin (18, 19) . On the other hand, BMD-AM3 was less sensitive, and median MICs of both drugs were lower. ROC-derived breakpoints for all methods (including BMD-AM3) demonstrated improved sensitivity at no cost to specificity. Indeed, susceptibility testing of anidulafungin using an Etest resistance breakpoint of Ͼ0.06 g/ml and micafungin using a YeastOne resistance breakpoint of Ͼ0.03 g/ml showed they were the most sensitive methods for detecting FKS mutants. For patients infected with isolates demonstrating MICs above ROC-derived breakpoints, the positive predictive values for echinocandin treatment failure were 80% (8/10) and 57% (12/21), respectively.
Regardless of testing method, anidulafungin and micafungin MICs were best interpreted in the context of prior echinocandin exposure (Fig. 2) . Using ROC-derived breakpoints for each agent, treatment failure rates ranged from 78 to 89% among patients previously exposed to an echinocandin and infected with a resistant strain of C. glabrata. The failure rates were 42 to 50% among previously exposed patients who were infected with susceptible strains and only 20% (9/45) for patients who did not have prior echinocandin exposure (regardless of strain susceptibility). Our previous findings using ROC-derived caspofungin breakpoints were comparable (Fig. 2C) . Taken together, the data highlight that microbiologic resistance is not the sole determinant of responses to antifungal therapy, as factors like host immune function, underlying diseases, severity of illness, intravenous catheter removal, adjunctive surgical interventions, and pharmacokinetic/pharmacodynamic parameters also play crucial roles (20) . The small number of patients included in this study precludes our ability to draw definitive conclusions about the relative merits of using FKS mutant detection, echinocandin MIC determinations, or a history of prior echinocandin to guide treatment decisions. The detection of an FKS mutation or the presence of echinocandin resistance among patients who have previously received an echinocandin virtually ensures treatment failure. Our experience suggests that the most judicious course is to use an agent from an alternative antifungal class in treating patients with previous echinocandin exposure.
In conclusion, future studies are needed to validate our findings and clarify the roles of echinocandin susceptibility testing and FKS mutant detection in clinical practice. In addition, studies of other Candida species must be undertaken. A major challenge for the field is to identify susceptibility testing methods that minimize variability in caspofungin MICs. In the meantime, our data suggest that anidulafungin or micafungin MICs may be more reliable predictors of treatment failure against C. glabrata invasive candidiasis, even among patients who are treated with caspofungin.
